Safe Use of Proton Pump Inhibitors
This document has been prepared by a multiprofessional collaborative group, with support from the All Wales Prescribing Advisory Group (AWPAG) and the All Wales Therapeutics and Toxicology Centre (AWTTC), and has been endorsed by the All Wales Medicines Strategy Group (AWMSG).

Please direct any queries to AWTTC:

All Wales Therapeutics and Toxicology Centre
University Hospital Llandough
Penlan Road
Llandough
Vale of Glamorgan
CF64 2XX

awttc@wales.nhs.uk
029 2071 6900

This document should be cited as:
All Wales Medicines Strategy Group, Safe Use of Proton Pump Inhibitors. February 2018.
KEY MESSAGES

- Proton pump inhibitor (PPI) use in Wales has continued to increase (by nearly 25% over the last 6 years), with PPI prescribing 14% higher than in England.

- The evidence base around the adverse effects from long-term use of PPIs is increasing.

- Prescribers should only use PPIs for recognised indications and appropriate durations to minimise PPI overuse and the associated increased risk of harm.

- Adverse effects include a greater risk of fractures, hypomagnesaemia and infections, including \textit{Clostridium difficile} infection.

- Older people may be more susceptible to the adverse effects of long-term PPI use.
Safe Use of Proton Pump Inhibitors

CONTENTS

1.0 PROTON PUMP INHIBITOR PRESCRIBING ................................................................. 3
  1.1 Managing dyspepsia symptoms before starting PPI therapy ....................................... 3
  1.2 Medicines that cause or increase risk of dyspepsia, gastrointestinal bleeding or ulceration ................................................................. 4
  1.3 Short-term PPI prescribing ........................................................................................... 4
  1.4 Helicobacter pylori eradication ..................................................................................... 4
  1.5 Long-term PPI prescribing ............................................................................................ 5
  1.6 Risk of gastrointestinal bleeding from medicines use .................................................. 5
  1.7 Antiplatelets and PPI use ............................................................................................. 5
  1.8 Non-steroidal anti-inflammatory drugs and PPI use .................................................... 6
  1.9 Other medicines requiring possible PPI use ................................................................ 6
  1.10 PPI choice ................................................................................................................... 6

2.0 PPI SAFETY ..................................................................................................................... 7
  2.1 Higher mortality ............................................................................................................ 7
  2.2 Fractures ....................................................................................................................... 7
  2.3 Clostridium difficile infection ......................................................................................... 7
  2.4 Pneumonia .................................................................................................................... 8
  2.5 Acute interstitial nephritis ............................................................................................. 8
  2.6 Chronic kidney disease ................................................................................................. 8
  2.7 Hypomagnesaemia ....................................................................................................... 9
  2.8 Vitamin B₁₂ deficiency .................................................................................................. 9
  2.9 Cardiovascular events .................................................................................................. 9
  2.10 Subacute cutaneous lupus erythematosus .............................................................. 10
  2.11 Cancer ...................................................................................................................... 10

3.0 OPTIMISING PPI USE ................................................................................................... 10
  3.1 PPI review ................................................................................................................... 10
  3.2 Healthcare professionals’ role in managing PPI use ................................................. 11

4.0 USEFUL RESOURCES .................................................................................................. 11

5.0 REFERENCES ............................................................................................................... 12

APPENDIX 1: MANAGEMENT OF DYSPEPSIA ................................................................. 16

APPENDIX 2: RELATIVE RISK OF DIAGNOSED UPPER GASTROINTESTINAL BLEEDING DURING EXPOSURE TO SPECIFIC MEDICINE GROUPS IN MONOTHERAPY AND COMBINATION THERAPY ................................................................. 17

APPENDIX 3: PPI REVIEW: MAIN ACTION POINTS ......................................................... 18

APPENDIX 4: PPI REVIEW TOOLKIT ................................................................................. 19

APPENDIX 5: PATIENT INFORMATION LEAFLET ................................................................ 26
1.0 PROTON PUMP INHIBITOR PRESCRIBING

In Wales the prescribing of proton pump inhibitors (PPIs) has risen by nearly 25% over the last six years. Wales has a 14% higher prescribing rate than England, with an estimated 11% of the population receiving monthly PPI prescriptions. In 2016, over £6.5 million was spent on PPIs in primary care in Wales. The PPIs currently available are: esomeprazole, lansoprazole, omeprazole, pantoprazole and rabeprazole. PPIs are generally used to treat common gastrointestinal symptoms, such as dyspepsia, as well as to prevent harm from other medicines, for example, peptic ulcers caused by non-steroidal anti-inflammatory drugs (NSAIDs).

PPIs are generally well tolerated, with a low incidence of adverse effects associated with short-term use. However, there is increasing evidence that long-term PPI use is associated with an increased risk of adverse effects. Some of these adverse effects, such as fractures and *Clostridium difficile* infection, are themselves associated with considerable morbidity and mortality, as well as high treatment costs.

1.1 Managing dyspepsia symptoms before starting PPI therapy

Before starting PPI therapy, people should be given lifestyle advice (Table 1) and encouraged to self-treat with an antacid and/or alginate. This approach is effective in controlling symptoms for many people. A flow diagram detailing the management of dyspepsia is provided within Appendix 1.

Table 1. Lifestyle advice for people with dyspepsia

<table>
<thead>
<tr>
<th>Advice to help with dyspepsia symptoms</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lose weight (if the person is overweight)</td>
<td></td>
</tr>
<tr>
<td>Stop smoking</td>
<td></td>
</tr>
<tr>
<td>Stop or reduce alcohol consumption</td>
<td></td>
</tr>
<tr>
<td>Stop or reduce intake of any food or drink associated with worsening symptoms (e.g. fatty foods, coffee, chocolate)</td>
<td></td>
</tr>
<tr>
<td>Eat meals at regular times, avoiding large or late meals</td>
<td></td>
</tr>
<tr>
<td>Avoid bending over or lying down immediately after eating</td>
<td></td>
</tr>
<tr>
<td>Use antacid and/or alginate when necessary for immediate symptom relief after meals and at bedtime</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Advice to help with reflux symptoms when lying down</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Avoid meals within 3 to 4 hours of going to bed</td>
<td></td>
</tr>
<tr>
<td>Raise the head of their bed by 10 to 20 cm (4 to 8 inches) using blocks under the legs of the bed</td>
<td></td>
</tr>
<tr>
<td>Use antacid when necessary and/or alginate for immediate symptom relief at bedtime</td>
<td></td>
</tr>
</tbody>
</table>
1.2 Medicines that cause or increase risk of dyspepsia, gastrointestinal bleeding or ulceration

Certain medicines can cause or increase the risk of dyspepsia, gastrointestinal bleeding or ulceration; these include:

- Antiplatelets e.g. aspirin (including 75 mg)
- Anticoagulants
- Corticosteroids
- NSAIDs
- Antibiotics
- Selective serotonin reuptake inhibitors (SSRIs)
- Bisphosphonates
- Calcium-channel blockers
- Iron
- Nitrates e.g. isosorbide mononitrate
- Nicorandil
- Theophylline and aminophylline
- Others: colchicine, levodopa, digoxin, potassium chloride

Each medicine or medicine group offers a different risk factor for dyspepsia, gastrointestinal bleeding or ulceration. These risks will additionally be influenced by medicine dosage, frequency and co-prescribing, as well as patient factors such as age, lifestyle and co-morbidities. For estimated upper gastrointestinal bleeding risk of different medicines and medicine groups, please see Table 2.

1.3 Short-term PPI prescribing

When defined short-term courses are prescribed, the person’s symptoms should be reviewed on course completion and the PPI discontinued as appropriate. Some people may need to have repeated short courses of PPI treatment (2 to 3 times a year) to control their symptoms. Alternatively, others may benefit from taking PPIs on an “as-needed” basis.

PPIs can be prescribed in short-term use for indications including:

- treating peptic ulcers (usually a 4 to 8 week course)
- eradicating *Helicobacter pylori* (*H. pylori*) infection (1 to 2 week course in combination with antibiotics)
- treating dyspepsia and gastro-oesophageal reflux disease (GORD) (4 to 6 week course if medication review and lifestyle advice are ineffective):
  - for uninvestigated dyspepsia (continuously for 4 weeks or intermittently to control symptoms)
  - for symptomatic functional dyspepsia, after *H. pylori* eradication (for 4 weeks)
  - for severe GORD (for 4 to 6 weeks before titrating down).

1.4 *Helicobacter pylori* eradication

In adults with dyspeptic symptoms that are persistent or recurrent despite treatment, one option is to test for the presence of *H. pylori*, and eradicate if present. PPIs are an integral part of *H. pylori* eradication regimens and are typically given in combination with antibiotics. Prescribers should refer to local guidance to be informed of the recommended PPIs for their locality. Prescribers should seek further advice from a gastroenterologist if eradication of *H. pylori* is not successful after first- and second-line treatment regimens.
1.5 Long-term PPI prescribing

Long-term PPI exposure may lead to adverse effects and should only be used if people have an established clinical need. In people receiving long-term courses the prescriber should clearly document the indication, and the person should be regularly reviewed to assess and check for adverse effects.

PPIs can be prescribed in long-term use for indications including:
- control of excessive acid secretion in people with Zollinger-Ellison syndrome
- prevention and treatment of NSAID-associated ulcers, and/or NSAID-related dyspeptic symptoms
- maintaining remission in severe GORD
- gastroprotection in people with a history of dyspepsia who require aspirin after a cardiovascular or cerebrovascular event
- preventing relapse in people with gastric and duodenal ulcers
- GORD that is refractory to other treatments
- acid reflux disease.

The 2015 WeMeReC bulletin “Proton pump inhibitors” states: “the NICE recommendations for using PPIs as maintenance, longer-term, are relatively selective and include severe oesophageal stricture, Barrett’s oesophagus, and those requiring gastroprotection when considered at high-risk of GI complications with regular NSAID use.”

1.6 Risk of gastrointestinal bleeding from medicines use

NSAIDs, anticoagulants and antiplatelets cause over a third of hospital admissions due to avoidable adverse drug reactions (ADRs). Gastrointestinal bleeds are implicated in half of the deaths from primary care ADRs. A case series analysis has estimated the incidence rate ratio (IRR) of upper gastrointestinal bleeding in relation to specific medication groups. These medicines, as monotherapies with their associated IRRs, are listed in Table 2. Appendix 2 provides the associated IRRs of these medicines when used in specific combinations.

### Table 2. Relative risk of diagnosed upper gastrointestinal bleeding during exposure to specific medicine groups (with corresponding 95% confidence intervals) as monotherapy

<table>
<thead>
<tr>
<th>Medication group</th>
<th>IRR (95% confidence interval)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Non-selective NSAIDs</td>
<td>4.27 (4.11-4.44)</td>
</tr>
<tr>
<td>Corticosteroids</td>
<td>4.07 (3.83-4.32)</td>
</tr>
<tr>
<td>Aldosterone antagonists</td>
<td>3.27 (3.06-3.50)</td>
</tr>
<tr>
<td>Low-dose aspirin</td>
<td>3.05 (2.94-3.17)</td>
</tr>
<tr>
<td>Anticoagulants</td>
<td>3.01 (2.85-3.19)</td>
</tr>
<tr>
<td>Cyclooxygenase-2 selective inhibitors</td>
<td>2.90 (2.67-3.15)</td>
</tr>
<tr>
<td>Nitrates</td>
<td>2.55 (2.43-2.68)</td>
</tr>
<tr>
<td>Selective serotonin reuptake inhibitors</td>
<td>2.06 (1.94-2.18)</td>
</tr>
<tr>
<td>Antiplatelet (excluding low-dose aspirin)</td>
<td>1.74 (1.61-1.87)</td>
</tr>
<tr>
<td>Gastroprotective agents</td>
<td>1.61 (1.56-1.66)</td>
</tr>
<tr>
<td>Calcium channel blockers</td>
<td>1.57 (1.51-1.63)</td>
</tr>
</tbody>
</table>

1.7 Antiplatelets and PPI use

A study of long-term antiplatelet therapy in secondary prevention of vascular disease showed that the severity, case fatality and poor functional outcome of bleeds increase with age. In people aged 75 years and over, most major upper gastrointestinal bleeds are disabling or fatal. PPIs are recommended in older people who are receiving aspirin-based antiplatelet treatment.
Because of a probable interaction, the Medicines and Healthcare products Regulatory Agency (MHRA) has advised that the combination of clopidogrel with omeprazole or esomeprazole should be avoided, unless considered essential. Current evidence does not extend this advice to other PPIs. For further details of this interaction and others involving PPIs, refer to the British National Formulary and appropriate summaries of product characteristics.

1.8 Non-steroidal anti-inflammatory drugs and PPI use
Gastrointestinal bleeding and ulceration can occur with NSAID treatment. The risk of serious gastrointestinal side effects varies between individual NSAIDs: piroxicam, ketoprofen and ketorolac are associated with the highest risk, and ibuprofen (up to 1.2 g daily) is associated with the lowest risk.

Not all people who are prescribed an NSAID will need gastroprotection to prevent adverse effects. People at high risk of NSAID-induced ulcers, when the NSAID cannot be discontinued, should be prescribed a PPI (at a dose licensed for gastroprotection) to protect against peptic ulceration. The PPI will need to be continued for the duration of the NSAID treatment, and reviewed for discontinuation when the NSAID is stopped.

1.9 Other medicines requiring possible PPI use
Some medicines can cause or increase the risk of dyspepsia, gastrointestinal bleeding, or ulceration. Any medicine identified to be causing gastrointestinal symptoms of clinical significance should be reviewed. Where appropriate this medicine can be considered for discontinuation and a suitable alternative prescribed. In those circumstances where this is not preferable and it is clinically justified gastroprotection can be considered in the form of a PPI.

1.10 PPI choice
Differences between PPIs in terms of clinical efficacy and safety are minimal. No PPI is more effective than another at equivalent doses, and so the National Institute for Health and Care Excellence (NICE) recommends using the least expensive PPI. Branded preparations and alternative formulations, such as dispersible tablets, are less cost effective than standard generic formulations. Unlicensed liquid formulations (specials) are considerably more expensive and should be reserved for hospital specialist initiation. If treatment with one PPI is ineffective, switching to an alternative PPI is a cost-effective therapeutic strategy.
2.0 PPI SAFETY

As PPIs have become more widely used, evidence continues to emerge about their safety and the potential for adverse effects. Most of these adverse effects appear to be associated with long-term PPI use. Suspected adverse effects to PPIs should be reported to the MHRA through the Yellow Card reporting scheme.

Most of the evidence for the possible long-term harmful effects of PPIs comes from case reports and observational data. Some studies have calculated the numbers needed to harm (NNH); however, this is not always possible because much of the data around PPI adverse effects are from observational studies. Randomised controlled trials would have a reduced risk of bias, but those conducted to date often have small numbers of patients and are too short to detect rarer events. Therefore, the findings of well-designed observational studies should be considered and are described in this section, including appropriate statistical calculations. It may be that in these studies, patients who need long-term PPIs have worse health overall than the patients with whom they are being compared. Therefore, some information is provided for consideration when prescribing on an individual patient basis rather than stating wide prescribing recommendations.

2.1 Higher mortality

A recent observational study of people taking PPIs showed that their all-cause mortality increased the longer they took them. People who received PPIs for between one and two years had a 50% increased risk of death compared with those who took them for less than a month. An increased risk of death was also associated with the lack of a documented gastrointestinal indication for PPI use.

The higher risk of death with PPI use is likely to be mediated by the occurrence of one or more of the adverse events associated with PPI use, for example, osteoporotic fracture, chronic kidney disease, hypomagnesaemia, and *Clostridium difficile* infection. Long-term PPI use should be limited to people who have a clear medical indication and in whom the benefits will outweigh any potential risks.

2.2 Fractures

In 2012 the MHRA said there was an increased risk of bone fractures associated with long-term use of PPIs. This was largely based on observational studies suggesting that PPIs may cause a modest increase in the risk of hip, wrist or spine fracture, especially if used in high doses over durations of more than one year. The increased risk was seen mainly in older people. A more recent meta-analysis of 18 observational studies concluded that PPI use modestly increased the risk of any-site fracture (relative risk [RR] 1.33, 95% confidence interval [CI] 1.15 to 1.54). However, there was no determinable difference between short- or long-term use.

The possible mechanism for PPI-induced increased fracture risk remains largely unexplained; one proposed theory is the decreased absorption of calcium due to increased pH in the small intestine. However, a causal relationship is yet to be established so other factors could be contributing to the increased risk.

No association between PPI use and osteoporosis has been demonstrated. However, the MHRA recommends that people at risk of osteoporosis who need PPIs should be treated according to current clinical guidelines to ensure they have an adequate intake of vitamin D and calcium. If necessary, they should also receive other preventative therapy, such as bisphosphonates.

2.3 *Clostridium difficile* infection

The weight of evidence appears to support an association between PPI use and an increased risk of *Clostridium difficile* infection (CDI). A MeReC Rapid Review highlighted a large observational study showing that hospitalised patients taking daily PPIs were
over 70% more likely to develop CDI than those not taking PPIs\textsuperscript{20,21}. People who already had CDI and were treated with PPIs had a more than 40% increased relative risk of infection recurrence\textsuperscript{22}.

Although a causal link has not yet been proven, because gastric acid is thought to play a principal role in sterilising the stomach contents entering the digestive tract, it is plausible that raising the pH of the stomach with a PPI may increase the load of pathogenic microbes. However, it is possible that these associations are confounded by other CDI risk factors\textsuperscript{4}. These include older age, antibiotic treatment, underlying morbidity, hospitalisation, and history of CDI\textsuperscript{23}. Prescribers should consider reviewing the need for, and stopping, PPIs in people with CDI or at high risk of CDI\textsuperscript{4,24}.

A speculative estimate of the number needed to harm with PPI use has been stated at around 4,000 people at 1 year. For hospitalised patients receiving antibiotics this reduced significantly to 50 people at 1 year after two weeks of admission\textsuperscript{25}.

2.4 Pneumonia

There is conflicting evidence for an increased risk of community-acquired pneumonia (CAP) with PPI treatment. A meta-analysis from 2010 found an association between PPI use and CAP\textsuperscript{26}. A separate study found that this association was particularly strong during the first seven days of PPI treatment\textsuperscript{27}. However, a more recent population-based study concluded that any association between the use of PPIs and risk of CAP is likely to be due entirely to confounding factors\textsuperscript{28}.

Further research is needed into a link between PPI and CAP before the impact on clinical practice can be determined\textsuperscript{4}. However, it seems that caution is warranted when prescribing PPIs for older people who are at increased risk of infection and for whom pneumonia may be an important cause of morbidity and mortality, and for people with asthma or chronic obstructive pulmonary disease\textsuperscript{29,30}.

2.5 Acute interstitial nephritis

Acute kidney injury is a common cause for admission to hospital\textsuperscript{31} and acute interstitial nephritis is a common cause of acute kidney injury. An association has been reported between acute interstitial nephritis and PPIs\textsuperscript{32,33}. A population-based, cohort, observational study investigated PPIs and the risk of acute interstitial nephritis and acute kidney injury in older people. It showed a higher rate of acute interstitial nephritis (0.32 vs. 0.11 per 1,000 person-years; hazard ratio [HR] 3.00; 95% CI 1.47 to 6.14), and acute kidney injury (13.49 vs. 5.46 per 1,000 person-years; HR 2.52; 95% CI 2.27 to 2.79) in people taking PPIs than among the control group\textsuperscript{34}.

In acute interstitial nephritis a first option is to immediately discontinue the PPI; spontaneous recovery occurs after withdrawal in most cases\textsuperscript{33}. PPIs can often be replaced with lifestyle measures, an antacid and/or alginate treatment, and/or ranitidine (which is very rarely associated with acute interstitial nephritis)\textsuperscript{35}.

Because PPIs are often co-prescribed with NSAIDs, there is a possibility that the PPI could be overlooked as the causative agent of the acute kidney injury. Any patient presenting with deteriorating renal function who has been prescribed both a PPI and an NSAID should have both medicines reviewed.

2.6 Chronic kidney disease

The results of a cohort analysis suggest an association between PPI use and chronic kidney disease (CKD) without an intervening acute kidney injury\textsuperscript{36}. The association of PPI use with CKD suggests that monitoring for acute kidney injury or acute interstitial nephritis in people taking PPIs may not be sufficient to guard against developing CKD and end-stage renal disease\textsuperscript{36}.
In early 2017, the Pharmacovigilance Risk Assessment Committee of the European Medicines Agency concluded that there is insufficient evidence for a causal relationship between PPIs and incident CKD and progression to end-stage renal disease to warrant an update of the product information or any additional risk minimisation measure. However, future periodic safety update reports should consider any further evidence as it emerges.

The possible mechanisms of PPI-related renal injury are poorly evidenced at present and there is a need for a greater understanding of the effects of PPIs on the kidney before any definite recommendations can be made. However, prescribers should be vigilant to these adverse effects and periodically monitor renal function in people taking PPIs long-term.

### 2.7 Hypomagnesaemia

The MHRA has warned of the risk of hypomagnesaemia with PPI use. Hypomagnesaemia occurs most commonly after one year of PPI treatment. Serious manifestations of hypomagnesaemia – fatigue, tetany, delirium, convulsions, dizziness, and ventricular arrhythmia – can occur, but they may begin insidiously and may be overlooked.

Routinely monitoring serum magnesium levels in all people taking a PPI is not recommended. However, measuring serum magnesium levels should be considered before prescribing PPIs to people who will be taking them on a long-term basis and particularly to people who will also be receiving digoxin, diuretics or other treatments associated with hypomagnesaemia. Measurements should be repeated periodically during long-term PPI treatment. Magnesium supplementation is the standard treatment for hypomagnesaemia, but in approximately 25% of cases reviewed, supplementation alone did not improve low serum magnesium levels and PPI treatment had to be discontinued.

### 2.8 Vitamin B12 deficiency

Gastric acid is needed to cleave vitamin B12 from ingested dietary proteins and enable it to be absorbed. Therefore, PPIs, which suppress gastric acid production, may lead to malabsorption of vitamin B12.

A large case-control study of more than 200,000 people found a significantly (65%) increased risk of vitamin B12 deficiency associated with taking PPIs for two or more years. The same study found a 25% increased risk with the use of H2 receptor antagonists e.g. ranitidine. Further studies are needed to clarify the clinical significance of these associations.

Routinely monitoring vitamin B12 in all people taking a PPI is not recommended. However, people at particular risk of vitamin B12 deficiency include older or malnourished people taking PPIs for more than one year and people taking other medicines that can affect vitamin B12 levels, such as metformin.

### 2.9 Cardiovascular events

An association has been observed between PPI use and adverse cardiovascular outcomes in people at high cardiovascular risk. Among patients with GORD, taking a PPI was associated with a 16% increased risk of myocardial infarction. This association does not in itself provide proof of causation, and further studies are needed. When appropriate, prescribers should consider reducing PPI doses, or stopping PPI treatment if possible, in people with existing cardiovascular disease and no strong indication for PPI therapy.
2.10 Subacute cutaneous lupus erythematosus
The MHRA has advised that PPIs are associated with infrequent cases of subacute cutaneous lupus erythematosus which can occur weeks, months or even years after exposure. In most cases, symptoms resolve on stopping PPI treatment.

2.11 Cancer
PPI use is associated with increased serum gastrin levels and bacterial overgrowth, resulting in an increased formation of toxic bile salts. Concerns that this may increase the risk of developing gastric cancer have been raised. A recent population-based study considered the risk of developing gastric cancer with long-term PPI use after H. pylori eradication treatment. It reported an association of PPIs with an increased gastric cancer risk even after H. pylori eradication therapy. The stated adjusted absolute risk difference for excess gastric cancer in PPI use versus non-PPI use was 4.29 per 10,000 person-years (95% CI 1.25 to 9.54). The study identified a dose-response and time-response trend of PPI use and gastric cancer risk.

3.0 OPTIMISING PPI USE
In view of the increased evidence about the adverse effects of PPIs, particularly from long-term use, prescribers are encouraged to use PPIs judiciously. Treatment should be given at the lowest effective dose that controls symptoms, and for the minimum period of time. The use of short courses, as-needed doses, and encouraging people to self-treat with antacid and/or alginate therapy should be commonplace unless there is a recognised indication for long-term PPI treatment.

3.1 PPI review
After people have completed defined courses, PPIs should be reviewed and discontinued as appropriate. PPIs should be reviewed between 4 and 8 weeks after starting treatment. For people prescribed long-term PPI therapy, NICE recommends that a medicines review of the PPI is done at least annually. A suggested methodology for a PPI review is shown schematically in Appendix 3. A PPI review toolkit is available in Appendix 4, including an algorithm for deprescribing PPI therapy.

Up to 30% of people may be able to stop PPI therapy immediately after the first course without experiencing symptoms. However, rebound hypersecretion (a rise in acid secretion after discontinuing PPI treatment) can occur after courses as short as 8 weeks’ duration. This can often lead to an increase in gastrointestinal symptoms, which may be mistaken for disease relapse. The duration of rebound hypersecretion is unknown, but some studies show reflux-like symptoms within 2 weeks, and for at least 4 weeks after withdrawal from PPI therapy.

To help limit the occurrence of rebound hypersecretion, the dose of PPI could be reduced gradually and an antacid and/or alginate could be prescribed for at least 2 weeks. If a step-down approach does not adequately control symptoms, treatment could be resumed with the lowest effective dose of PPI, with consideration to future step-down when appropriate. Prescribers should talk with the patient about the options available for stepping down therapy, considering their preferences in developing the step-down plan.
General PPI prescribing recommendations
The following points may help to ensure appropriate prescribing of a PPI:

- before a PPI is started, prescribers should consider lifestyle changes and review other medications where possible
- PPIs should only be prescribed in line with clinical guidelines and the reason for starting should be clearly documented
- intermittent courses should be used, typically for 4 to 8 weeks
- all newly initiated PPIs should be reviewed after the first 4 to 8 week course
- a PPI should not be continued as a repeat prescription unless there is a clear indication
- long-term PPI prescriptions should be reviewed at least annually
- long-term care should emphasise patient empowerment by encouraging lifestyle changes and by promoting symptomatic use of antacids and/or alginate and when appropriate using the lowest effective dose of a PPI, ideally in short courses or on an ‘as needed’ basis
- during PPI withdrawal, a regular antacid and/or alginate therapy should be prescribed for a minimum of 2 weeks to stop rebound acid hypersecretion.

3.2 Healthcare professionals’ role in managing PPI use
All healthcare professionals can offer advice and support to people who are prescribed PPIs.

This involvement could include:

- providing people with the patient information leaflet on PPIs (see Appendix 5)
- advising people that PPIs should be taken between 30 minutes and 60 minutes before breakfast
- providing lifestyle advice, for example, on healthy eating, weight loss or stopping smoking
- referring people to their GP if they present with symptoms needing further investigation, or when prescribed medication has not provided adequate symptom relief
- participating in a multidisciplinary audit of PPI prescribing
- community pharmacists advising on over-the-counter medications for relief of gastrointestinal symptoms, including managing the symptoms of indigestion and reflux through the Common Ailments Service
- community pharmacists undertaking medicines use reviews working with local GP practices to focus on patients who have been prescribed long-term PPIs.

4.0 USEFUL RESOURCES

Welsh Medicines Resource Centre:
Bulletin: Proton pump inhibitors

National Institute for Health and Care Excellence:
Clinical Guideline CG184: Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management

Medicines and Healthcare products Regulatory Agency:
Proton pump inhibitors: very low risk of subacute cutaneous lupus erythematosus

Drug Safety Update: Proton pump inhibitors in long-term use: increased risk of fracture

Drug Safety Update: Clopidogrel and proton pump inhibitors: interaction – updated advice
5.0 REFERENCES


APPENDIX 1: MANAGEMENT OF DYSPEPSIA
(Adapted from NICE Clinical Guideline 184 and original All Wales guidance produced by Dr Miles Allison while working with National Leadership and Innovation Agency for Healthcare, 2008)

Symptoms at presentation:
Dyspepsia (indigestion): upper abdominal pain or discomfort, heartburn, acid reflux, nausea or vomiting

Review and consider:
Heart, liver, gallbladder, pancreas, bowel
Excess alcohol
Stopping NSAIDs, including aspirin, and other medication which may cause/increase risk of dyspepsia
Offer:
Lifestyle advice

Dyspepsia and significant acute GI bleeding

Any of the following: upper abdominal mass consistent with stomach cancer, dysphagia, aged 55 and over with weight loss and any of the following: upper abdominal pain, reflux, dyspepsia

Immediate (same day) specialist referral

Predominant heartburn or acid regurgitation

Urgent direct access endoscopy (within two weeks)

Non-urgent direct access endoscopy

Endoscopy findings

Dyspepsia and significant acute GI bleeding

Any of the following: haematemesis (when urgent admission is not required), treatment resistant dyspepsia, or upper abdominal pain with low haemoglobin levels, or raised platelet count with any of the following: nausea, vomiting, weight loss, reflux, dyspepsia, upper abdominal pain, or nausea or vomiting with any of the following: weight loss, reflux, dyspepsia, upper abdominal pain

Persistent or recurrent symptoms

H. pylori stool antigen test

Positive

Eradicate H. pylori (refer to local guidance)

Aged 55+

Unresolved

Unresolved

Aged < 55

H. pylori urea breath test

Positive

2nd line eradication (refer to local guidelines)

Unresolved

Unresolved

Consider hospital referral

Yes

No

Yes

No

Yes

No

Yes

No

Yes

No

Yes

No
APPENDIX 2: RELATIVE RISK OF DIAGNOSED UPPER GASTROINTESTINAL BLEEDING DURING EXPOSURE TO SPECIFIC MEDICINE GROUPS IN MONOTHERAPY AND COMBINATION THERAPY

(Taken from Masclee G, Valkhoff V, Coloma P et al. Risk of Upper Gastrointestinal Bleeding from Different Drug Combinations. Gastroenterology. 2014;147:784-792.)

Table 2: Relative Risk of Diagnosed UGIB During Exposure to Specific Drug Groups (With Corresponding 95% CIs) in Monotherapy and in Combination With Other Drugs

<table>
<thead>
<tr>
<th>Drug groups</th>
<th>Monotherapy</th>
<th>Combination with nsNSAIIDs</th>
<th>Combination with COX-2 inhibitors</th>
<th>Combination with Low-dose aspirin</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n</td>
<td>IRR (95% CI)</td>
<td>n</td>
<td>IRR (95% CI)</td>
</tr>
<tr>
<td>No drug*</td>
<td>69,694</td>
<td>1.00 (reference)</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>nsNSAIIDs</td>
<td>3327</td>
<td>4.27 (4.11-4.44)</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>COX-2 inhibitors</td>
<td>635</td>
<td>2.90 (2.67-3.15)</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Low-dose aspirin</td>
<td>4733</td>
<td>3.05 (2.94-3.17)</td>
<td>418</td>
<td>6.77 (6.09-7.53)</td>
</tr>
<tr>
<td>Corticosteroids</td>
<td>1376</td>
<td>4.07 (3.83-4.32)</td>
<td>244</td>
<td>12.82 (11.17-14.42)</td>
</tr>
<tr>
<td>SSRIs</td>
<td>1793</td>
<td>2.06 (1.91-2.18)</td>
<td>210</td>
<td>6.95 (5.37-8.06)</td>
</tr>
<tr>
<td>OPAs</td>
<td>5279</td>
<td>1.61 (1.56-1.67)</td>
<td>678</td>
<td>3.90 (3.59-4.24)</td>
</tr>
<tr>
<td>Aldosterone antagonists</td>
<td>1211</td>
<td>3.27 (3.06-3.50)</td>
<td>75</td>
<td>11.00 (8.63-14.00)</td>
</tr>
<tr>
<td>Calcium channel blockers</td>
<td>3616</td>
<td>1.57 (1.51-1.63)</td>
<td>353</td>
<td>4.45 (3.98-4.98)</td>
</tr>
<tr>
<td>Anticoagulants</td>
<td>1300</td>
<td>3.01 (2.80-3.21)</td>
<td>143</td>
<td>6.69 (5.30-10.35)</td>
</tr>
<tr>
<td>Antplatelets (excluding low-dose aspirin)</td>
<td>994</td>
<td>1.74 (1.61-1.87)</td>
<td>87</td>
<td>6.50 (5.19-8.15)</td>
</tr>
<tr>
<td>Nitrites</td>
<td>2572</td>
<td>2.55 (2.43-2.68)</td>
<td>172</td>
<td>5.82 (4.97-6.62)</td>
</tr>
</tbody>
</table>

NOTE. n refers to the number of UGIB events during exposure to specific drug groups (the total number does not add up to 114,835 because of diagnoses of UGIB in "other drug category"); NA, not applicable.
*No use of the predefined drugs of interest.
APPENDIX 3: PPI REVIEW: MAIN ACTION POINTS

**Is the patient receiving a PPI regularly as part of their repeat prescription order?**

- Yes
  - Is there a clinical reason for long-term treatment?
    - Yes
      - Maintain treatment with current PPI and agree period for review.
      - Ensure the indication is documented in medical notes.
      - Provide lifestyle advice.
      - Ensure adequate intake of calcium and vitamin D in patients at risk of fractures.
      - Consider measuring magnesium and vitamin B12 levels, and renal function before starting PPI and repeat measurements periodically during prolonged treatment.
      - Consider future step down where appropriate.
    - No
      - Review prescription and address lifestyle issues.
      - Can PPI be stopped or stepped down?
        - Step down:
          - Consider “as-needed” PPI treatment with regular self-care*.
        - Stop PPI:
          - Start gradual dose reduction, with co-prescription of antacid and/or alginate for at least two weeks to reduce rebound hypersecretion.
      - Manage repeats:
        - Remove from repeat prescribing and/or prescribe for specific durations.
      - If patient has a reason for “as-needed” use, ensure an appropriate frequency of supply.
      - Record review in notes and monitor progress.

- No
  - Symptom return
    - Use regular antacid and/or alginate.
    - Revert to lowest effective PPI dosage as needed for up to four weeks.
    - Consider regular PPI use until symptoms resolve and then re-start step-down with self-care*.

* Self-care
  - Give patients lifestyle advice.
  - Advise patients to use antacids and/or alginate first line to control symptoms.
  - Review use of medicines known to cause GI adverse effects.
APPENDIX 4: PPI REVIEW TOOLKIT

Purpose of document
This audit and review has been developed by the Welsh Analytical Prescribing Support Unit (WAPSU). The document is for use in primary care to highlight prescribing and possible patient safety issues with PPIs. It will be available on the AWMSG website.

Background
Quality improvement toolkits have been developed to assist in collating and auditing information. These are produced with reference to evidence-based practice and priorities in Wales. They should be seen as good practice and are intended to improve data quality and help development within the practice.

Improvements in practice will be optimised by multidisciplinary involvement in the audit and team discussion of the results. It is recommended that action plans implemented after this audit are reviewed within six months and that a re-audit is done if possible in 6 to 12 months.

Aims
- To ensure adequate, timely review of all patients receiving a PPI, in line with NICE guidance.
- To minimise the use of high acquisition cost (HAC) PPIs.
- To ensure all patients on long-term PPIs are receiving these for appropriate indications and are being monitored regularly for potential adverse effects.
- To ensure all patients on long-term PPIs have their magnesium and vitamin B₁₂ levels, and renal function, monitored.
- To ensure all patients on long-term PPIs have an adequate intake of calcium and vitamin D.

Objectives
- To identify all patients over the age of 18 years receiving long-term PPI and where appropriate, discontinue treatment, reduce the dose or move to ‘as-needed’ administration.
- To identify all patients requiring continued long-term PPI treatment and investigate for adverse effects.
- To identify all patients prescribed HAC PPIs and, where appropriate, stop or switch to a low acquisition cost (LAC) alternative.

Inclusion criteria
- All patients over the age of 18 years receiving:
  - four or more prescriptions (acute or repeat) for a PPI in the last six months.

Exclusion criteria
- Other medical situations where changes to medication would be inappropriate, e.g. chemotherapy, palliative care or a mental health condition.
- Under 18 years of age.
- Patients who need a medicine that has potential to cause gastrointestinal symptoms e.g. NSAID.
- Patients for whom “as-needed” treatment or self-care is not appropriate including those with a history of benign oesophageal stricture, Zollinger–Ellison syndrome or Barrett’s oesophagus.

Prioritisation
All patients prescribed PPIs should be reviewed. However, it may not be appropriate to consider changes to PPI treatment in some patients. In patients where a previous PPI switch has been attempted and was not successful, consider why it was unsuccessful; do these factors still apply?

Preparation
- The auditor should brief practice staff about the review.
- Local community pharmacists should be informed of the review to enable them to provide supporting advice.
The review process

1.0 Identify patients receiving a prescription for a PPI who meet the inclusion criteria

Use the GP clinical database system to search for all patients over the age of 18 years who have:

- been prescribed a HAC PPI in the last six months (acute or repeat prescription)
- a PPI on their repeat prescription (for 28 days or equivalent)
- collected four or more prescriptions for a PPI in the last six months.

Include the generic name and brand name for each medicine in the search. Some computer systems will allow a search on the action group for PPIs to avoid having to enter the medicine names individually.

Table 1. PPIs currently available for prescribing in Wales.

<table>
<thead>
<tr>
<th>Generic name</th>
<th>Brand name</th>
</tr>
</thead>
<tbody>
<tr>
<td>Esomeprazole</td>
<td>Nexium®</td>
</tr>
<tr>
<td>Lansoprazole</td>
<td>Zoton®</td>
</tr>
<tr>
<td>Omeprazole</td>
<td>Losec®</td>
</tr>
<tr>
<td>Pantoprazole</td>
<td>Protium®</td>
</tr>
<tr>
<td>Rabeprazole</td>
<td>Pariet®</td>
</tr>
</tbody>
</table>

Note: remember to include all formulations of PPIs including dispersible tablets and liquid specials

2.0 Complete the data collection sheet

A sample data collection form for PPI review is included. This can be adapted for local use. Use the patients’ medical records to complete these forms.

3.0 Identify patients suitable for review or discontinuation of treatment

Review patients for their continuing need for a PPI, or their suitability for a reducing the dose, “as-needed” use or a switch to a cost-effective alternative (e.g. change from a HAC to a LAC PPI; change to a more cost-effective formulation). Use the flow diagram in Appendix 3.

4.0 Authorise the change

If the review is completed by a non-GP, make sure that each dose reduction, move to “as-needed” management or discontinuation of use is authorised by the patient’s own GP or as agreed within the practice.

All reviews and dose changes should be clearly documented in the medical notes. If the change is not authorised, the reason for this should be recorded in the patient’s medical notes.

If a patient is to remain on a HAC PPI, record the reason for this in the patient’s medical notes.

In every case where the review results in a patient remaining on long-term regular PPIs, record the reason for this in the patient’s medical notes. All patients remaining on long-term regular PPI treatment should be counselled on adequate calcium and vitamin D intake, and should have a blood test to monitor serum magnesium levels periodically during treatment, especially patients who will take a PPI concomitantly with digoxin or medicines that may cause hypomagnesaemia (e.g. diuretics).
5.0 Changes to the patient’s medical notes
Remove the PPI from repeat prescription for all patients who have not collected a prescription in the last six months. This will prompt a review of symptoms if a request for the PPI is made again.

Add the details of the new medication and changes in dose or directions to the patient’s current medication record, ensuring that the non-proprietary (generic) formulation is selected. Document the change in the medical notes.

Remove the medication to be discontinued from the patient’s repeat prescribing list on the current medication record.

Document the reasons for all changes in the patient’s medical notes, e.g. therapeutic substitution, switch to LAC PPI or removal of high-risk medication such as an NSAID. Ensure the indication for the PPI is documented.

6.0 Notify the patient about changes to their medication
Send an appropriate letter to each patient, informing them of the changes made to their medication.

Alternatively, send a letter inviting a patient to attend for review and discussion, make the changes during a face-to-face consultation.

A Patient Information Leaflet (PIL), “Stopping Your PPI” (in English and Welsh), is provided in Appendix 5 and is also available on the AWMSG website.

7.0 Keep a record
Keep a separate record of all patients for whom the PPI dose has been altered or stopped.

8.0 Arrange follow-up monitoring
Arrange a follow-up for some patients, when considered necessary. This could be patients who are particularly concerned.

9.0 At follow-up
Ensure that the patient’s symptoms remain controlled, and if they are not discuss an appropriate way forward to regain control.

Record those patients for whom a treatment switch is unsuccessful and all reasons why, to inform future attempts.

10.0 Summary of review
Use the GP practice summary form to review all changes made and to measure the effectiveness of the change programme.
### INDIVIDUAL DATA COLLECTION FORM FOR PPI REVIEW

<table>
<thead>
<tr>
<th>Patient name/ID</th>
<th>Medicine</th>
<th>Dose</th>
<th>Formulation</th>
<th>Last collected</th>
<th>What is the dosing schedule?</th>
<th>Regularly</th>
<th>PRN</th>
<th>Unknown</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Who initiated/recommended current PPI? (Tick most appropriate)

<table>
<thead>
<tr>
<th>GP</th>
<th>Hospital discharge</th>
<th>Pharmacist</th>
<th>Hospital specialist</th>
<th>Other, please specify</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Is the patient on any medication which may interact with the PPIs (most importantly clopidogrel (omeprazole/esomeprazole), warfarin, phenytoin)? Please state

<table>
<thead>
<tr>
<th>Indication for PPI? (Tick all that apply)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Endoscopically confirmed GORD</td>
</tr>
<tr>
<td>Endoscopically confirmed peptic ulcer disease</td>
</tr>
<tr>
<td>Endoscopically negative reflux disease or functional (non-ulcer) dyspepsia</td>
</tr>
<tr>
<td>Zollinger–Ellison syndrome</td>
</tr>
<tr>
<td>Uncertain diagnosis, please specify</td>
</tr>
<tr>
<td></td>
</tr>
</tbody>
</table>

Prophylaxis of medicine-induced dyspepsia/ulceration, please specify medicine(s)

<table>
<thead>
<tr>
<th>Is there opportunity to review the medicine(s)?</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
</tbody>
</table>

H. pylori testing (if indicated)

Has the patient been tested for H. pylori?

<table>
<thead>
<tr>
<th>Has the patient been tested for H. pylori?</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
</tr>
</tbody>
</table>

If positive, has this patient had H. pylori eradication therapy?

<table>
<thead>
<tr>
<th>If positive, has this patient had H. pylori eradication therapy?</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
</tr>
</tbody>
</table>

Has the patient received lifestyle advice?

<table>
<thead>
<tr>
<th>Has the patient received lifestyle advice?</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
</tr>
</tbody>
</table>

Has a previous switch/review been undertaken? If yes, give details

<table>
<thead>
<tr>
<th>Has a previous switch/review been undertaken? If yes, give details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
</tr>
</tbody>
</table>

Has the patient been on another PPI previously? If yes, give details

<table>
<thead>
<tr>
<th>Has the patient been on another PPI previously? If yes, give details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
</tr>
</tbody>
</table>

Has the dosage of the PPI been changed during the current course of treatment? If yes, give details

<table>
<thead>
<tr>
<th>Has the dosage of the PPI been changed during the current course of treatment? If yes, give details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
</tr>
</tbody>
</table>

Is the patient on long-term PPIs (> 1 year)?

<table>
<thead>
<tr>
<th>Is the patient on long-term PPIs (&gt; 1 year)?</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
</tr>
</tbody>
</table>

If yes:

Has the patient had a PPI review in the last 12 months?

<table>
<thead>
<tr>
<th>Has the patient had a PPI review in the last 12 months?</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
</tr>
</tbody>
</table>

Has the patient had their serum magnesium monitored? (BNF states measurement of serum magnesium concentrations should be considered before and during prolonged treatment with a PPI; important in patients on long-term PPIs who are also receiving digoxin, diuretics or other medicines known to cause hypomagnesaemia)

<table>
<thead>
<tr>
<th>Has the patient had their serum magnesium monitored?</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
</tr>
</tbody>
</table>

Has the patient been advised about calcium and vitamin D intake/taking calcium and vitamin D supplements? (Patients at risk of osteoporosis should be treated in line with current guidelines to ensure adequate calcium and vitamin D)

<table>
<thead>
<tr>
<th>Has the patient been advised about calcium and vitamin D intake/taking calcium and vitamin D supplements?</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
</tr>
</tbody>
</table>

Have the following patient factors been considered: vitamin B₁₂ deficiency, renal function, Clostridiu diffficile infection, pneumonia?

<table>
<thead>
<tr>
<th>Have the following patient factors been considered:</th>
</tr>
</thead>
<tbody>
<tr>
<td>vitamin B₁₂ deficiency, renal function, Clostridiu diffficile infection, pneumonia?</td>
</tr>
<tr>
<td>Yes</td>
</tr>
</tbody>
</table>

Is there a reason for not reviewing PPI in this patient (see possible exclusions)?

<table>
<thead>
<tr>
<th>Has the patient been identified as being able to change from their current PPI/dose to a more suitable alternative?</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
</tr>
</tbody>
</table>

If yes, what action is the most appropriate for this patient?

<table>
<thead>
<tr>
<th>If yes, what action is the most appropriate for this patient?</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reduce dose of LAC PPI at regular usage – state dose and directions</td>
</tr>
<tr>
<td>Reduce to LAC PPI at PRN usage with self-care – state dose</td>
</tr>
<tr>
<td>Switch from HAC PPI to LAC PPI – state PPI and dose</td>
</tr>
</tbody>
</table>
Stop PPI (remove PPI from repeat if not collected for > six months). If long-term PPI, consider reducing PPI dose before stopping or provide acute prescription of an antacid and/or alginate for 2–4 weeks to prevent rebound hypersecretion

Other, please state

**Proposed action (tick when completed)**

- Send letter to patient inviting them to make appointment for review
- Send letter to patient informing them of change, enclose PIL explaining change

Action to be completed by:

<table>
<thead>
<tr>
<th>Completed by</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Reviewed and authorised by (GP sign)</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>
## GP PRACTICE SUMMARY FORM

### Pre-review

<table>
<thead>
<tr>
<th>Description</th>
<th>Number</th>
<th>Percentage of practice population</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>PRACTICE LIST SIZE</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Number of patients in the practice identified in step 1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Number of patients prescribed a LAC PPI</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Number of patients prescribed a HAC PPI</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Number of patients suitable for inclusion in the review</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Documentation

<table>
<thead>
<tr>
<th>Description</th>
<th>Quantity</th>
<th>Percentage of patients reviewed</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of patients with a documented indication for therapy when PPI initially prescribed</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Number of patients with a documented indication for long-term use</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Number of patients who have had lifestyle advice documented in their notes within the last 12 months</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Number of patients who have had a review of their PPI in the last 12 months</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Number of patients on long-term treatment who have had their serum magnesium monitored</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Number of patients with whom calcium and vitamin D intake has been discussed/supplements being taken</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Summary of interventions made

<table>
<thead>
<tr>
<th>Description</th>
<th>Quantity</th>
<th>Percentage of patients reviewed</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total number of patients: Dose of LAC PPI reduced</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total number of patients: LAC PPI reduced to “as-needed” use and self-care</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total number of patients: Stop PPI (encourage self-care with antacid and/or alginate)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total number of patients: Switch from HAC PPI to LAC PPI</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Post review summary

<table>
<thead>
<tr>
<th>Description</th>
<th>Number</th>
<th>Percentage of practice population</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>PRACTICE LIST SIZE</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Number of patients in the practice on a PPI</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Number of patients prescribed a LAC PPI</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Number of patients prescribed a HAC PPI</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
PPI DEPRESScribing ALGORITHM (TAKEN FROM PRESCQIPP)

Proton Pump Inhibitor (PPI): Deprescribing algorithm (adults)

Why is the patient prescribed a PPI? Does prescribing follow recommendations in NICE CG184?
If unsure, find out if the patient:
- Has previously had an endoscopy.
- Is taking PPI for gastroprotection against an ulcerogenic medicine.
- Has ever been hospitalised for a bleeding ulcer.
- Has ever had heartburn or dyspepsia.

Indication still unknown?
- Mild to moderate oesophagitis or
- GORD treated x 4-8 weeks (oesophagitis healed, symptoms controlled)
- Peptic ulcer disease treated for 2-12 weeks (from NSAID use; H. pylori).
- Upper GI symptoms without endoscopy; asymptomatic for 3 consecutive days.
- ICU/surgery stress ulcer prophylaxis treated beyond a hospital admission.
- Uncomplicated H. pylori treated for 2 weeks and now asymptomatic.

Documented history of any of the following:
- Barrett’s oesophagus
- Severe oesophagitis
- History of bleeding GI ulcer
- On-going, uncontrolled GORD
- Used for gastro-protection as patient is co-prescribed a potentially ulcerogenic medicine:
  - Antiplatelets
  - Anticoagulants
  - Corticosteroids
  - SSRI + NSAID.

Recommend deprescribing the PPI
- Taper to lower dose: Evidence suggests no increased risk in return of symptoms compared with continuing higher dose. OR
- Stop and use on demand: Daily until symptoms stop [10% of patients may have return of symptoms].

Stop the PPI
If potentially ulcerogenic medicine(s) stopped.

Continue the PPI

Monitor at 4 & 12 weeks for:
- Heartburn
- Dyspepsia
- Regurgitation
- Epigastric pain
- Loss of appetite
- Weight loss

Non-pharmacological interventions:
- Avoid meals 2-3 hours before bedtime.
- Elevate head of bed.
- Address if a need for weight loss.
- Avoid dietary triggers, e.g. caffeine, chocolate, fatty foods.
- Smoking cessation.
- Reduce/stop alcohol intake.

Manage occasional symptoms using:
- Over the counter: Antacid, alginate, PPI, H2RA - take as required.
- H2RA daily [up to 20% of patients may have return of symptoms].

If symptoms relapse:
If symptoms persist for between 3-7 days and interfere with normal activity:
1) Test and treat for H. pylori, if present. 2) Consider returning to previous dose. 3) Further attempt to stop the PPI after 2-4 weeks of continued therapy.
APPENDIX 5: PATIENT INFORMATION LEAFLET
(see following page)
• If your symptoms are worse at night, try raising the head of the bed by 10 to 20 cm (4 to 8 inches) using blocks under the legs of the bed.
• Stop or reduce your alcohol consumption. Do not regularly drink more than 14 units per week. If you do drink as much as this, it is best to spread this evenly across 3 days or more. If you feel that you have a problem with alcohol, talk to a healthcare professional.
• Stop smoking. Discuss ways to quit smoking with a healthcare professional or call “Help Me Quit” free on 0800 085 2219.

**What should I do if I develop problems?**

You should talk to a healthcare professional if:
• your symptoms do not get any better, or they get worse
• you experience vomiting, especially if this contains blood or material that looks like coffee grounds
• your bowel movements are dark and sticky
• swallowing is difficult or painful
• you have unexplained weight loss.

**Seek urgent medical attention** if you experience chest pain that gets worse with or after exercise, or pain that goes into your chin or left shoulder—as this type of pain may be a sign of a heart problem.

**STOPPING YOUR PPI**

**What is a PPI?**

PPIs, or proton pump inhibitors, are a group of medicines that are used to reduce the amount of acid that your stomach makes. By lowering the acid level, they can help relieve symptoms and prevent harm.

You will have been given one of the following PPIs:
- esomeprazole
- omeprazole
- rabeprazole
- lansoprazole
- pantoprazole

**Why am I taking a PPI?**

Your healthcare professional will talk with you about why a PPI might be helpful and how long you should take it for. This will depend on why you are taking it, because PPIs can be used for lots of different reasons.

**How long should I take my PPI for?**

To start with, you may be given a PPI for 4 weeks. If your symptoms continue then you may be given another 4-week course.

Many people find that after 4 to 8 weeks of taking a PPI their symptoms are better. After this time you should stop taking the PPI.
Why should I stop my PPI treatment?

Your healthcare professional has decided that you no longer need to take a PPI. This will help prevent any side effects that can be caused by long-term PPI treatment. Unwanted side effects of long-term PPI treatment include increased risk of fractures, infections, and low magnesium.

If you are unsure why your PPI is being stopped, or you would like to discuss this further, then ask a healthcare professional. You should only be taking PPIs long-term if there is a definite need, which your healthcare professional has discussed with you.

How will I stop my PPI?

Your healthcare professional will usually recommend one of three options for stopping your PPI. These are:

1. Stop taking the PPI
   You may be advised to stop taking your PPI, either straightaway or when your current supply is finished, and take an antacid and/or alginate if you still have symptoms. An antacid neutralises the acid in your stomach, and an alginate prevents acid flowing into your oesophagus (food pipe).

2. Take PPI only when needed
   You may be advised to take your PPI only when you have symptoms. When the symptoms are relieved (often after a few days) you would then stop taking the PPI.

3. Reduce PPI dose
   If you have taken your PPI for several months, and particularly if you have been taking a high dose, your healthcare professional may reduce your PPI dose for a few weeks before stopping it.

What if my symptoms come back?

Some people find that when they stop taking their PPI, their symptoms return and may even seem worse than before they started treatment. This is because if you take a PPI for more than a few weeks, your stomach will try to increase its ability to make acid. This means that for a while after you stop taking your PPI, the acid levels in your stomach may be higher than before you started treatment.

Your healthcare professional may give you an antacid and/or alginate. If needed, these can help to control your symptoms until your acid levels return to normal. Alternatively, you may be given a medicine known as an H2-receptor antagonist, such as ranitidine, which works in a similar way to a PPI but has fewer long-term side effects.

If you have symptoms when you stop taking your PPI and you have not been offered any other medicine, or if you think the medicine you’ve been given is not working, you should talk to a healthcare professional.

What can I do to help?

Lifestyle advice for helping with symptoms:
- Keep to a healthy weight.
- Avoid food and drink that make your symptoms worse, such as spicy or fatty foods, chocolate, coffee, cola drinks, orange juice.
- Eat meals at regular times.
- Avoid large or late meals and avoid bending over or lying down immediately after eating.
- Avoid medicines that can make symptoms worse, for example, some painkillers. Ask a healthcare professional which medicines are best for you to take.
Defnydd Diogel o Atalwyr Pwmp Proton

Tudalen 29 o 30

O yw eich symptomau’n waeth yn y nos, ceisiwch godi pen eich gwely 10 i 20cm (4 i 8 modfedd) gan ddefnyddio blociau o dan goesau'r gwely

• Stopiwch neu lleihewch faint o alcohol rydych yn ei yfed. Peidiwch ag yfed mwy na 14 uned yr wythnos yn rhoalaidd. Os ydych chi’n yfed gymaint à hyn, mae’n well ei wasgaru’n gyfartal ar draws 3 neu fwy o ddiwrnodau. Os ydych yn teimlo bod gennych broblem gydag alcohol, siaradwch à gweithiwr gofal iechyd proffesiynol.

• Rhowch y gorau i ysmygu. Trafodwch ffrdd i roi’r gorau i ysmygu gyda gweithiwr gofal iechyd proffesiynol, neu ffoniwch “Helpa Fi i Stopio” am ddim ar 0800 085 2219.

Beth ddylwn ei wneud os caf broblemau?

Dylech siarad à gweithiwr gofal iechyd proffesiynol:

• os nad yw eich symptomau’n gwella, neu eu bod yn gwaethygu
• os ydych yn chwydu, yn arbenig os yw’n cynnwys gwaed neu ddeunydd sy’n edrych fel gronynnau coffi
• os yw eich carthion yn dywyl a gludiog
• os yw llyncu’n anodd neu’n boenus
• os byddwch yn colli pwysau heb esboniad

Ceisiwch sylw meddygol ar frys os cewch boen yn y frest sy’n gwaethygu gyda neu wedi ymarfer corff, neu boen sy’n mynd i mewn i’ch gên neu’ch ysgwydd chwith - gan y gall y math hwn o boen fod yn arwydd o broblemau’r galon.

I’w lenwi gan gweithiwr gofal iechyd proffesiynol:

Enw’r PPI a stopiwyd:

Meddyginiaethau a roddwyd i reoli symptomau (os yn berthnasol):

Enw’r gweithiwr gofal iechyd proffesiynol:

Rhif cyswllt:

Beth yw PPI?

 Gnwp o feddyginiaethau a ddefnyddir i leihau faint o asid y mae eich stumog yn ei greu yw PPI, neu atalwyr pwmp proton. Drwy ostwng lefel yr asid, gallant helpu i liniaru symptomau ac atal niwed.

Byddwch wedi derbyn un o’r PPI canlynol:

• esomeprazole
• omeprazole
• rabeprazole

Pam fy mod yn cymryd PPI?

Bydd eich gweithiwr gofal iechyd proffesiynol yn siarad â chi ynglŷn à chi ynglŷn à pham y gallai PPI fod yn ddefnyddio ac am faint o amser y dylech ei gymryd. Bydd hyn yn dilynir ar pam eich bod yn ei gymryd, oherwydd gellir defnyddio PPI am lawer o wahanol resymau.

Am faint ddylwn i gymryd fy PPI?

I ddechrau, efallai y rhoddir PPI i chi am 4 wythnos. Os bydd eich symptomau’n parhau yna efallai y rhoddir cwrs 4 wythnos arall i chi.

Bydd llawer o bobl yn teimlo bod eu symptomau’n well wedi 4 i 8 wythnos o gymryd PPI. Wedi hyn dylech stopio cymryd y PPI.
Bydd eich gweithiwr gofal iechyd proffesiynol wedi penderfynu nad oes angen i chi gymryd PPI hirdymor. Mae sgîl-effeithiau nas dymunir triniaeth PPI yn cynnwys perygl cynyddol o doresgyrn, heintiau a lefelau isel o fagnesiwm.

Os nad ydych chi’n siŵr pam fod eich PPI yn cael ei stopio, neu os hoffech drafod hyn ymhellach, yna holwch weithiwr proffesiynol. Dylech ond bod yn cymryd PPI yn hirdymor os oes angen penodol, y bydd eich gweithiwr gofal iechyd proffesiynol wedi’i drafod gyda chi.

Os ydych wedi bod yn cymryd PPI am nifer o fisoedd, ac yn enwedig os ydych wedi bod yn cymryd dos uchel, efallai y bydd eich gweithiwr gofal iechyd proffesiynol yn lleihau eich dos PPI am ychydig wythnosau cyn ei stopio’n llwyr.

Welthiau gall symptomau ddychwelyd, o bosibl ar ôl nifer o fisoedd. Os digwydd hyn dylech siarad â gweithiwr gofal iechyd proffesiynol.

Cyngor ffordd o fyw ar gyfer helpu â symptomau:
• Cadwch at bwysau iach.
• Osgowch fwyddyd a diodydd sy’n gwaethu eich symptomau, megis bwyddyd sbeislyd neu frasterog, sioeled, coffi, diodydd cola, sudd oren.
• Bwyteuch brydau ar adegau rheolaidd.
• Osgowch brydau mawr neu hwyrc ac osgowch blygu drosodd neu orwedd i lawr yn syth ar ôl bwyta.
• Osgowch feddyniaethau a allai waethu eich symptomau, er enghraiff hrai cyffuriau lladd poen. Gofynnwch i weithiwr gofal iechyd proffesiynol pa feddyniaethau sydd orau i chi eu cymryd.